This is a single center cross-sectional imaging study investigating the use of gallium-68
citrate PET in patients with metastatic castration-resistant prostate cancer who are planning
to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519).
The study population will consist of patients with metastatic castration-resistant prostate
cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001
(CC#125519), with evidence of resistance to androgen signaling inhibition.
The study will involve gallium-68 PET scan obtained at single time point, followed by
radiographically-guided metastatic tumor biopsy within 14 days of PET scan.